![Julian Symons](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 205 756 $ in data 31/08/2026
Julian A. Symons is Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. since 2018.
Formerly, Dr. Symons was Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Education includes a doctorate from York University and an undergraduate degree from the University of Central Lancashire.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 35.112 ( 0,64% ) | 205 756 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2018 |
| Società | Posizione | Fine |
|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Corporate Officer/Principal | 01/04/2018 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
York University
 York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Central Lancashire
 University of Central Lancashire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aligos Therapeutics, Inc.
 Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
